Navigation Links
Vasogen Announces Second Quarter 2009 Results
Date:7/14/2009

monetization of certain tangible and intangible assets. The process has also included a review of the potential out-licensing of assets, lapsing of patents and patent applications, asset divestiture, or liquidation of the Company. The process involved narrowing down the number of third-party proposals. At this time, we are in the process of negotiating agreements that may result in one or more transactions with regard to the foregoing. There can be no assurances that we will be able to finalize any such agreements. The Board will also consider alternatives to these that it has also been evaluating. The Board will continue to assess the merits of these options relative to liquidating the Company and distributing the remaining cash to the shareholders.

The unaudited interim consolidated financial statements, accompanying notes to the unaudited interim consolidated financial statements, and Management's Discussion and Analysis for the three and six months ended May 31, 2009, will be accessible on Vasogen's website at www.vasogen.com and will be available on SEDAR and EDGAR.

Certain statements in this document constitute "forward-looking statements" within the meaning of the United States Private Securities Litigation Reform Act of 1995 and/or "forward-looking information" under the Securities Act (Ontario). These statements may include, without limitation, plans to consider a sale, merger, acquisition, or other alternatives resulting from our strategic review, statements regarding the status of development, or expenditures relating to the Celacade System or our VP series of drugs including VP015 and VP025, plans to fund our current activities, statements concerning our partnering activities, health regulatory submissions, strategy, future operations, future financial position, future
'/>"/>

SOURCE Vasogen Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. Vasogen Announces Third Quarter Conference Call and Webcast of Bio InvestorForum 2007 Presentation
2. Vasogen Announces Third Quarter 2007 Results
3. Vasogen to Webcast Presentations at Three Upcoming Healthcare Conferences
4. Vasogen Provides an Update on ACCLAIM-II Preparations
5. Vasogen and Grupo Ferrer Announce Initial Roll-out of Celacade - New Therapy for Chronic Heart Failure
6. Vasogen to Conduct Year-end 2007 Conference Call
7. Vasogen Announces 2007 Year-End Results
8. The Lancet Publishes Vasogens ACCLAIM Results
9. Vasogens Research Published in European Journal of Neuroscience
10. Vasogen to Present at the BIO CEO & Investor Conference and Participate on the Non-Cancer Immunotherapy Panel
11. Vasogen Provides Update on ACCLAIM II Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... Dec. 17, 2014 Tigercat Pharma, Inc. ... study evaluating the investigational oral NK-1 receptor antagonist ... severe, chronic itch who are unresponsive or inadequately ... topical steroids and antihistamines. The ... Analog Scale (VAS) itch score from baseline, comparing ...
(Date:12/15/2014)... YORK , Dec. 15, 2014  GlassesOff Inc. ... Yuval Bar-Gil as an independent director of the ... founder of AeroScout and served as its CEO until ... in 2012, a $240 million transaction. Recognized as the ... Mr. Bar-Gil,s leadership, AeroScout provided Wi-Fi -based RFID solutions ...
(Date:12/13/2014)... Clarassance, a privately held clinical-stage biotechnology company based ... Therapeutics , Inc. The new name is derived from ... in the lungs similar to branches on a tree), ... therapeutics for the treatment of respiratory diseases. , ... to mark the company's escalation into the clinical phase ...
(Date:12/13/2014)... December 13, 2014 QuickSTAT is making ... and Cold Chain capabilities, and is delighted to announce ... France, to serve Life Science clients in the region. ... a controlled-ambient warehouse, will provide 24/7 transportation and logistics ... investigational drugs, patient-clinical specimens, API, following IATA rules and ...
Breaking Biology Technology:Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 3Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 4AeroScout Founder Joins GlassesOff's Board of Directors 2AeroScout Founder Joins GlassesOff's Board of Directors 3Maryland-based Biotech Company's Path Forward in Treating Respiratory Diseases Sparks Name Change 2Quick Opens Office in France to Serve Life Science Community In France and Neighboring French-Speaking Countries 2
... America, Inc.  (OTC Bulletin Board: CBAI ) announced ... www.bancovida.com ) to offer umbilical cord blood collection services in ... will allow BancoVida and Cord Blood America to educate prospective ... of storing their baby,s umbilical cord blood.  The stem cells ...
... 26, 2011 Infrared Systems International (OTCBB: IFRS) announces ... strategies for continued success. Most recently, the ... its subsidiary, Infrared Applications, Inc. (IAI).  The distribution marks ... from one engaged in the aerospace industry to one ...
... Shire plc (LSE: SHP, NASDAQ: SHPGY ... U.S. Food and Drug Administration (FDA) has granted marketing approval ... attacks of hereditary angioedema (HAE) in adults 18 years of ... challenges gaining rapid access to acute treatment such as the ...
Cached Biology Technology:Cord Blood America Enters Agreement With BancoVida, a Cord Blood Collection Company in San Juan, Puerto Rico 2Infrared Systems International Reflects on Past and Looks Forward to the Future 2Infrared Systems International Reflects on Past and Looks Forward to the Future 3FDA Approves Shire's FIRAZYR® (icatibant injection) for Acute Attacks of Hereditary Angioedema (HAE) 2FDA Approves Shire's FIRAZYR® (icatibant injection) for Acute Attacks of Hereditary Angioedema (HAE) 3FDA Approves Shire's FIRAZYR® (icatibant injection) for Acute Attacks of Hereditary Angioedema (HAE) 4FDA Approves Shire's FIRAZYR® (icatibant injection) for Acute Attacks of Hereditary Angioedema (HAE) 5FDA Approves Shire's FIRAZYR® (icatibant injection) for Acute Attacks of Hereditary Angioedema (HAE) 6
(Date:11/21/2014)... REDMOND, Wash. , Nov. 20, 2014 ... access for the Internet of Things (IoT), today announced ... position of chief operating officer. Previously a strategic advisor ... marketing, finance, and operations. Mr. Traynor is based out ... . He reports to Chris Muench , ...
(Date:11/18/2014)... , Nov. 17, 2014   ... EMC collaborate to develop The Partners Data Lake, ... The Partners Data Lake will allow researcher and ... diagnostics, treatment and the lives of patients ... and clinical activities across the Partners system, breaking ...
(Date:11/15/2014)... 13, 2014  While we may still be a few ... in "Star Trek" to gain instant access to all that ... with smartphones and tablets for monitoring and measuring our health ... This may seem a tad Orwellian to some, but a ... of these technological opportunities into their healthcare regime. ...
Breaking Biology News(10 mins):C-Labs Names Former Microsoft and Bsquare Executive as Chief Operating Officer 2Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 2Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 3Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 4Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 5Americans May Be Ready for a Brave New World of Healthcare 2Americans May Be Ready for a Brave New World of Healthcare 3Americans May Be Ready for a Brave New World of Healthcare 4
... missing flu virus. When the flu isnt making people sick, ... Earth, it reappears in the appropriate season and starts its ... it hibernate, lying dormant in a few people and preparing ... Northern hemisphere to the Southern hemisphere and back, following the ...
... Researchers have discovered the secrets to enhancing youth ... 3-year study entitled Greener Voices proves that children ... responsibility for decisionmaking and planning. Childrens gardens ... are popping up in schools, communities, public venues, ...
... in Spanish . Breaking up the dosage ... of wheat and limits its negative effects on the environment. ... of the Basque Country (UPV-EHU) researcher, Teresa Fuentes Mendizbal, presented ... Wheat yields have increased over the decades, more concretely during ...
Cached Biology News:Tracking influenza's every movement 2Children's gardens mushrooming 2Dosage of fertilizer helps to enhance quality of wheat 2Dosage of fertilizer helps to enhance quality of wheat 3
Human TFPI Affinity Purified Polyclonal Ab Protein Family: Coagulation, Inflammation, Serine Protease Regulators...
TMB Slow Kinetic One Component HRP Microwell Substrate, 1 L...
Eppendorf tube holder, for Tube rack 175 x 12 mm, 100. Category: Chromatography Systems & Accessories, Systems....
Pooled normal sreum with 0.1% sodium azide as preservative...
Biology Products: